Skip to main content
  1. BAUS Home
  2. BAUS Annual Scientific Meeting
  3. About BAUS 2025
  4. Oncology

From Vish Hanchanale - Chair of the BAUS Section of Oncology

"... snappy headline ..."

The BAUS Section of Oncology is delighted to welcome you to Manchester for what promises to be an exceptional gathering of urological experts. Over the course of three days, we will explore cutting-edge advancements, debate the most pressing topics in uro-oncology, and, if history is anything to go by, engage in some lively and thought-provoking Q&A sessions.

This year’s programme is packed with a diverse range of sessions, from semi-live surgical video demonstrations to in-depth discussions on molecular innovations, emerging biomarkers, and the complexities of transplant urooncology.

We are privileged to host world-renowned experts, including Jean-Baptiste Roche from France, Hassan Abol-Enein from Egypt, Karel Decaestecker from Belgium, Damien Bolton from Australia, and Jose A Karam from the United States. Their presence offers a unique opportunity for our members to exchange scientific ideas, strengthen collaborations, and gain insights from global leaders in the field. We are also honoured to be joined by distinguished uro-oncologists Alison Birtle and Pasquale Rescigno, bringing a truly multidisciplinary approach to this year’s discussions.

Monday 16 June

The meeting begins on Monday with a session focused on precision and progress in uro-oncology. A Semi-Live Video Session will set the tone for the conference, showcasing the expertise of leading surgeons as they share innovative techniques and strategies. Jean-Baptiste Roche will present on vaginal and nerve-sparing female robotic cystectomy, while Hassan Abol-Enein will highlight diversion strategies for cases where healthy bowel segments are limited. Muddassar Hussain will provide insights into the intricacies of retroperitoneal robotic surgery, and Stefanos Bolomytis will address challenges in transperineal prostate biopsy. Raveen Sandher will delve into the nuances of partial orchidectomy and onco-microtesticular procedures, ensuring a comprehensive discussion on evolving surgical techniques. This session promises to challenge conventional thinking, enhance surgical skills, and stimulate discussion on innovative approaches to urological oncology.

Tuesday 17 June

On Tuesday, the spotlight will turn to innovations in prostate and bladder cancer. The morning session will explore genetic insights, biomarker advancements, and evolving treatment paradigms in prostate cancer. Pasquale Rescigno will examine the significance of germ line and somatic testing, while Zafer Tandogdu will discuss the shifting landscape of biochemical recurrence management strategies. Ashwin Sachdeva will present on tissue-based biomarkers and their potential to revolutionize prostate cancer diagnostics, management and surveillance. Taimur Shah will share the latest outcomes from the FORECAST trial, providing critical insights into focal therapy for radio-recurrent disease. This session will equip clinicians with the latest knowledge to navigate the rapidly evolving landscape of precision medicine in prostate cancer management.

The afternoon will focus on bladder and urothelial cancer. Param Mariappan will question the role of TURBT in muscle-invasive bladder cancer, prompting a discussion on whether it remains a cornerstone of modern management. Niyati Lobo will present provocative insights on active surveillance in nonmuscle-invasive bladder cancer, while Alison Birtle will explore the emerging role of circulating tumour DNA in diagnostics, paving the way for liquid biopsy innovations. Sustainability in uro-oncology is increasingly vital, and Joseph John will present preliminary findings from the ELLA audit, shedding light on sustainable practices in contemporary uro-oncology care.

To conclude the day, the focus will shift to transplant uro-oncology, with a session chaired by Alistair Rogers, Vishwanath Hanchanale, and Fiona McCaig. David Rix will discuss the challenges of managing renal cancer in transplant recipients, while Jonathon Olsburgh will address controversial topics such as active surveillance for prostate cancer in transplant patients. With the growing intersection of oncology and transplant medicine, this session will provide valuable guidance on handling complex cases. Karel Decaestecker will offer insights into advanced robotic transplantation techniques, and Rhana Zakri will explore the unique challenges of managing urothelial malignancy in transplant recipients.

Wednesday 18 June

The conference will conclude on Wednesday with a forward-looking session on the future of upper tract malignancies. James Blackmur will explore hereditary risk factors and their implications for patient counselling, while Jose A Karam will present the latest evidence on cytoreductive nephrectomy in metastatic renal cancer. Hannah Warren will introduce the novel KIM-1 biomarker in renal cancers, offering a glimpse into the potential of biomarker-driven treatment. The final session will see Bhavan Rai leading an evidence-driven discussion on radical nephroureterectomy for upper tract urothelial cancer, equipping attendees with the most up-to-date figures to inform their clinical decision-making.

Beyond the scientific discourse, BAUS 2025 will provide ample opportunities for networking, collaboration, and the exchange of ideas. Whether it is discussing complex cases over coffee, engaging in spirited debates during panel sessions, or brainstorming future research collaborations, this meeting is designed to foster a sense of community and innovation. We extend our sincere gratitude to all our outstanding speakers, participants, and organizers. Your dedication and contributions make this meeting a truly dynamic and impactful event. We encourage you to dive in, participate actively, and most importantly, enjoy the experience.